Entering text into the input field will update the search result below

Bristol Myers Opdivo combo gets FDA nod for expanded use in lung cancer

Mar. 07, 2022 4:27 AM ETBristol-Myers Squibb Company (BMY)By: Ravikash, SA News Editor2 Comments

Stock Markets Open One Day After Steep Drop Over Apple"s Revised Forecast

Drew Angerer/Getty Images News

  • The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) in combination with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting (use before surgery).

Recommended For You

Comments (2)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Seeking ROI profile picture
Announcements about new or expanded FDA approvals should include some indication of potential market size to be truly useful in evaluating significance. This is on the pharma companies to provide.
unless this is a sub-population that the FDA approved, which I dont think it is as it clearly says resectable, this may be the fastest approval ever. Just last week they issued a PR on the PDUFA date being approved with priority review of July 13th. So they filed, Jan 13th? If thats the case a Jan 13th filing with a March 4th approval is less than 2 months. Wow.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.